Schonfeld Strategic Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Schonfeld Strategic Advisors LLC

$13.8 Billion
Q3 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 70,771 shares of VRTX stock, worth $28.7 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares

70,771

Previous 38,245 85.05%

Holding current value

$28.7 Million

Previous $17.9 Million 83.61%

% of portfolio

0.24%

Previous 0.12%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $15 Million - $16.5 Million	32,526 Added 85.05%	70,771 $32.9 Million
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $6.53 Million - $8.07 Million	16,631 Added 76.95%	38,245 $17.9 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $8.81 Million - $9.64 Million	21,614 New	21,614 $9.03 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $9.08 Million - $9.73 Million	-26,848 Reduced 39.12%	41,775 $14.5 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $1.17 Million - $1.31 Million	-3,710 Reduced 5.13%	68,623 $24.1 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $18.4 Million - $21 Million	65,133 Added 904.63%	72,333 $22.8 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $2.33 Million - $2.62 Million	-8,143 Reduced 53.07%	7,200 $2.08 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $4.2 Million - $4.69 Million	15,343 New	15,343 $4.44 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $2.02 Million - $2.38 Million	-9,132 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $3.8 Million - $4.8 Million	-21,465 Reduced 70.15%	9,132 $2.01 Million
Q3 2021 Nov 16, 2021	BUY	$181.39 - $202.99 $2.83 Million - $3.17 Million	15,597 Added 103.98%	30,597 $5.55 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $4.19 Million - $4.94 Million	-22,348 Reduced 59.84%	15,000 $3.02 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $3.02 Million - $3.52 Million	14,584 Added 64.07%	37,348 $8.03 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $3.51 Million - $4.68 Million	16,937 Added 290.66%	22,764 $5.38 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $296,554 - $351,596	1,160 Added 24.86%	5,827 $2,000
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $229,313 - $300,828	1,017 Added 27.86%	4,667 $1.36 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $913,348 - $1.13 Million	-4,572 Reduced 55.61%	3,650 $869,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $3.98 Million - $5.35 Million	-23,878 Reduced 74.39%	8,222 $1.8 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $2.58 Million - $2.9 Million	15,500 Added 93.37%	32,100 $5.44 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $460,908 - $533,036	-2,800 Reduced 14.43%	16,600 $3.04 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $4.42 Million - $5.26 Million	-26,991 Reduced 58.18%	19,400 $3.57 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $3.43 Million - $4.34 Million	22,591 Added 94.92%	46,391 $7.69 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $3.99 Million - $4.59 Million	23,800 New	23,800 $4.59 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $948,200 - $1.11 Million	-6,507 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $283,340 - $331,055	1,869 Added 40.3%	6,507 $1.06 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $4.21 Million - $4.76 Million	-30,632 Reduced 86.85%	4,638 $695,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $5.22 Million - $5.72 Million	35,270	35,270 $5.36 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $104B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Vertex Pharmaceuticals Inc Transaction History